Drug Development – Talk Bio

Novartis Halts Phase 2 Osteoarthritis Study of ADAMTS-5 Inhibitor Due to Lack of Pain Relief

1 week ago talkbio0Tagged ADAMTS-5, cartilage degradation, Clinical Trial Termination, Degenerative polyarthritis, Drug Development, Inhibitor, Knee pain, M6495, Novartis, Pain, QUC398

Novartis, phase 2 trial, osteoarthritis, knee pain, ADAMTS-5 inhibitor, QUC398, M6495, clinical trial termination, pain relief, cartilage degradation, drug development

Cassava Sciences Discontinues Alzheimer’s Program After Simufilam Fails Second Phase 3 Trial

4 weeks ago talkbio0Tagged Alzheimer 's disease, Discontinuation (procedure), Drug Development, Failure (biologic function), Manihot esculenta, Phase 3 trial, Simufilam

Cassava Sciences, simufilam, Alzheimer’s disease, Phase 3 trial failure, drug development discontinuation

The Perfect Storm: Why 2025 Will Be the Year of GxP AI in Pharma

2 months ago talkbio0Tagged Administration occupational activities, Aortic Valve Insufficiency, data-driven innovation, Drug Development, GxP, pharmaceutical manufacturing, Quality, regulatory

GxP AI, pharmaceutical manufacturing, regulatory compliance, data-driven innovation, quality management, drug development

Major Clinical Trial Failures of 2024: Setbacks in Neuroscience and Beyond

2 months ago talkbio0Tagged Alzheimer 's disease, Amyotrophic Lateral Sclerosis, Clinical Trials, Drug Development, Duchenne, Neoplasms, Neuroscience discipline, Schizophrenia

Clinical trials, drug development, neuroscience, ALS, Alzheimer’s disease, schizophrenia, Duchenne muscular dystrophy, oncology

BioMarin’s R&D Chief Warns of Innovation Slowdown Amid NIH Funding Cuts

2 months ago talkbio0Tagged BioMarin, biomedical innovation, Drug Development, Hereditary Diseases, NIH Mouse, research partnerships

BioMarin, NIH funding, biomedical innovation, genetic diseases, drug development, research partnerships

Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment

2 months ago talkbio0Tagged Antisense, Biogen, Drug Development, Epilepsy, Infantile Severe Myoclonic Epilepsy, Infrequent, Oligonucleotides, pharmaceutical partnership, Stoke, Zorevunersen

Biogen, Stoke Therapeutics, zorevunersen, Dravet syndrome, antisense oligonucleotide, rare epilepsy, drug development, pharmaceutical partnership

AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies

2 months ago talkbio0Tagged AbbVie, Collaboration, Drug Development, engagers, Immunotherapy, Neoplasms, T-Lymphocyte, tumor-activated

AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development

Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects

2 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Capsid, Cu-Zn Superoxide Dismutase, Drug Development, Effect, gene therapy, off-target, payload, Preclinical, RNA, Small Interfering, Tracer, VY9323

SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay

Roivant’s Kinevant Discontinues Namilumab Development for Pulmonary Sarcoidosis After Phase 2 Failure

2 months ago talkbio0Tagged Drug Development, Failure (biologic function), Kinevant, namilumab, Phase 2 clinical trial, Roivant, Sarcoidosis, Pulmonary

Roivant Sciences, Kinevant, namilumab, pulmonary sarcoidosis, Phase 2 clinical trial, RESOLVE-Lung study, drug development failure

Eli Lilly Streamlines Pipeline, Removing Alzheimer’s and Obesity Candidates in Q4 2024

3 months ago talkbio0Tagged Alzheimer 's disease, Ceperognastat, Clinical Trials, Drug Development, Eli, Eli Lilly, Obesity, pipeline update

Eli Lilly, pipeline update, Alzheimer’s disease, obesity, ceperognastat, clinical trials, drug development